Chiesi Group Unveils a New Era in Biopharmaceuticals
Chiesi Group is taking a bold step into the future of medicine with a significant investment of €400 million for its new Biotech Center of Excellence. This landmark facility is designed to revolutionize the biopharmaceutical landscape, emphasizing integration throughout the production supply chain, thereby enhancing both innovation and productivity.
A Comprehensive Approach to Biotech Development
The state-of-the-art Biotech Center will focus on developing and producing monoclonal antibodies, enzymes, and various proteins. This facility aims to be a leader in Europe, providing an outstanding integrated approach where all processes occur under one roof. This includes everything from producing drug substances derived from mammalian cells to transforming them into final drug products, all delivered in a cohesive manner. The seamless marriage of research and production capabilities will significantly accelerate the transition of products from development to market.
By ensuring adaptability, this center will enhance Chiesi's capability to support an array of drug types, including both small and large batch productions. It will cater to both experimental and approved drugs, facilitating smoother transitions from clinical trials right into commercial manufacturing, making it a vital asset in Chiesi's operational strategy focused on respiratory care and treatments for rare diseases.
Commitment to Innovation and Collaboration
Chiesi Group's strategy underscores a robust emphasis on innovation, aligning with contemporary healthcare challenges. The Biotech Center of Excellence is positioned to foster a more resilient and sustainable biopharmaceutical system. By increasing production capabilities in Europe and attracting international talent and investment, Chiesi is poised to forge significant global partnerships. This ambitious project will devote more than 20% of its turnover to research and development, solidifying Chiesi’s status as a leader in R&D investment among Italian pharmaceutical companies.
According to Alessandro Chiesi, the Chair of Chiesi Group, the Biotech Center embodies a transformative step in healthcare. "We inaugurate a center with a production site that projects us into a new path of care, allowing us to continue making a difference in serving people and families living with chronic diseases, especially rare diseases, with increasingly innovative technologies. This facility will generate new knowledge and skills essential for attracting global talent," he emphasized.
The Vision and Future of Biopharmaceuticals
Giuseppe Accogli, CEO of Chiesi, expressed excitement over the center's potential impact, stating that innovation remains core to all that Chiesi values. “The opening of our new Biotech Center marks a bold leap forward in our commitment to delivering groundbreaking therapies that transform patients' lives. This establishment will elevate our production capabilities and deepen our dedication to fostering innovation,” he noted.
The recent launch event not only celebrated the operational opening of the center but also highlighted Chiesi's ongoing commitment to research within the biopharmaceutical sector, merging economic growth with high-quality job creation. Out of the total €400 million investment, €120 million is allocated for infrastructure advancements while €260 million will be dedicated over the next several years to essential materials, cutting-edge technologies, and workforce development.
The Center of Excellence is expected to employ up to 200 specialists, with the current team comprising 60 members, a number predicted to expand significantly in the following years. The therapeutic possibilities provided by the Biotech Center will firmly establish Chiesi as a leading entity in the rapidly evolving biopharmaceutical marketplace.
About Chiesi Group
Chiesi is a dynamic and research-driven international biopharmaceutical group that focuses on creating and marketing inventive therapeutic solutions in fields like respiratory health and rare diseases. The company's mission is to enhance life quality while ensuring responsible practices that benefit both society and the environment. By changing its legal status to a Benefit Corporation across key nations, Chiesi has made its commitment to sustainable, socially responsible value creation a core component of its operational framework. As a certified B Corporation since 2019, Chiesi adheres to high standards concerning social impact, and its vision includes achieving Net-Zero greenhouse gas emissions by 2035. With a rich legacy spanning over 85 years, Chiesi is headquartered in Parma, boasting 31 international affiliates and a workforce surpassing 7,000. The company's R&D center collaborates with six other critical R&D locations across the globe.
Frequently Asked Questions
What is the primary focus of Chiesi Group's new Biotech Center?
The primary goal is to develop and produce monoclonal antibodies, enzymes, and proteins with an integrated supply chain approach.
How much is Chiesi Group investing in the new center?
Chiesi Group is investing €400 million to establish the Biotech Center of Excellence.
What advantages does the new center offer for drug production?
The center allows for a seamless transition from drug development to commercial manufacturing, catering to various drug types and production volumes.
How many people will be employed at the new center?
Up to 200 specialists are expected to be employed at the center, with current staffing projected to grow significantly.
What is Chiesi Group's vision for the future?
Chiesi aims to foster innovation and sustainability in the biopharmaceutical sector while enhancing global collaborations and talent attraction.
